Novocure Ltd reports results for the quarter ended in September 30 - Earnings Summary

NovoCure

30/10/2024 15:20

* Novocure Ltd  NVCR.OQ  reported a quarterly adjusted loss
of 28
cents​​ per share for the quarter ended September 30, higher
than the same quarter last year, when the company reported EPS
of -46 cents.  The mean expectation of seven analysts for the
quarter was for a loss of 33 cents per share. Wall Street
expected results to range from -41 cents to -23 cents per share.
    * Revenue rose 21.8% to $155.10 million from a year ago;
analysts
expected $143.95 million. 
    * Novocure Ltd's reported EPS for the quarter was a loss
of 28
cents​.
    * The company reported a quarterly loss of $30.57 million.
    * Novocure Ltd shares had risen by 8.1% this quarter and
gained 13.1% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 0.4%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the medical
equipment,
supplies & distribution peer group is also "buy"

Wall Street's median 12-month price target for Novocure Ltd is
28.00 
This summary was machine generated from LSEG data October 30 at
03:20 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.33          -0.28          Beat
 Jun. 30 2024      -0.41          -0.31          Beat
 Mar. 31 2024      -0.42          -0.36          Beat
 Dec. 31 2023      -0.52          -0.45          Beat